Parsortix™ System
Capture and harvest of circulating tumour cells from whole blood.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The Parsortix system from ANGLE uses a patented micro-fluidic technology in the form of a disposable cassette to capture and then harvest circulating tumour cells (CTCs) from whole blood. The cassette captures CTCs based on their less deformable nature and larger size as compared to other blood components.
Benefits:
- Capture and harvest of CTCs for a wide range of cancers including prostate, breast, lung, colo-rectal, renal and ovarian.
- Cell capture does not require the use of antibodies hence allowing for capture of cells with weak cell marker expression (such as ovarian, liver and melanoma) as well as mesenchymal cells and clusters of cells.
- Ability to process up to 20ml of whole blood.
- Very simple operation with minimal user intervention required and no pre-processing of blood necessary.
- Customisable in-cassette staining protocols using up to six separate reagents.
- Harvest of intact CTCs in <100µl, ready for downstream analysis.
Applications:
- Enumeration of CTCs in patient blood samples.
- Harvesting of CTCs from patient blood ready for genetic or protein analysis such as: FISH, qPCR, Next generation sequencing, Immuno-histochemistry.
The Parsortix system is CE marked for use as an in vitro diagnostic device in the EU.
The system is available for research purposes in the US, but does not have FDA approval for clinical purposes.
Technical Validation of a Novel Label-Independent Device to Capture Circulating Tumor Cells
Circulating tumor cells (CTCs) are tumor derived biomarkers found in the blood of cancer patients with a wide range of clinical utility. This scientific poster explores the use of ANGLE’s Parsortix System as a novel marker-independent separation device for tumor cell enrichment, aiming to validate it as an effective device for the enrichment of epithelial and/or mesenchymal-like CTCs.
Evaluation of a Novel Microfluidic Device for Epitope-Independent Enrichment of Circulating Tumor Cells; ANGLE’s Parsortix System
Circulating tumour cells (CTCs) have potential utility as minimally-invasive biomarkers to aid treatment decision making. Many technologies that enrich CTCs based on expression of specific epitopes may miss CTC heterogeneity; new epitope-independent methods are needed. The Parsortix system from ANGLE uses a patented micro-fluidic technology in the form of a disposable cassette to capture and then harvest circulating tumour cells (CTCs) from blood. This scientific poster evaluated the capture and harvest efficiency of the Pasortix system as well as comparing it to the CellSearch system.
Intra-Tumour Heterogeneity in Prostate Cancer and the Implication in CTC Analysis using the Pasortix System
Isolation of circulating tumour cells (CTCs) from peripheral blood has the potential to provide a far easier ‘liquid biopsy’ than tumour tissue biopsies, to monitor tumour cell populations during disease progression and in response to therapies. This scientific poster describes the use of the Pasortix System in a study aimed to identify the heterogeneous expression of epithelial and mesenchymal markers in a metastatic prostate cancer cell line and to investigate the intra-patient heterogeneity of these sub-populations of circulating cells isolated by a size-based system.
Enrichment and Isolation of Uncontaminated Breast Cancer Cells from Human Blood Samples using ANGLE’s Parsortix System
Cancer cells in peripheral blood, known as circulating tumor cells (CTCs), play an important role in tumor dissemination. The molecular characterization of CTCs is important because it may provide insights into the molecular biology of metastasis, the association of their molecular profiles with treatment outcomes, and reveal the presence of potential therapeutic targets. This scientific poster presents a method used to isolate CTCs which combines the Parsortix System, microfluidic cell separation device, as an enrichment method followed by the DEPArray selection system. The ParsortixTM system is versatile in its ability to separate, capture and harvest CTCs in an enriched form compatible with the needs of downstream processes such as DEPArray.
Circulating Rare Cells Enable Highly Efficient Cancer Detection - Medical University of Vienna
Researchers from the Medical University of Vienna presented a scientific poster at the American Association of Cancer Research 2015 meeting, detailing a protocol combining the novel microfluidic Parsortix technology with qPCR, to enable the molecular analysis of circulating tumor cells (CTCs) implicated in ovarian and breast cancer. The Parsortix™ system was utilised for capturing and analyzing mRNA of circulating tumor cells. The new technique will allow the implementation of ‘liquid biopsies’ in cancer detection studies and as a companion diagnostic in clinical trials.
Angle’s Parsortix System Demonstrates Broader Ability to Capture Circulating Tumor Cells Versus Other Separation Technologies
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumor cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis
Angle’s Parsortix System Aids Important Findings Presented in Five Posters at AACR Annual Meeting April 16-20
Researchers’ use of ParsortixTM System for studies into multiple cancers confirms the cell separation technology’s ability to harvest viable circulating tumor cells for a broad range of downstream analyses
Top Clinical News Stories Last Month
Don't miss the most popular news stories of May 2015!
Early Detection of Ovarian Cancer: Medical University of Vienna Demonstrates ANGLE’s ‘Blood Biopsy’ Technology
Capture and analyze mRNA of circulating tumor cells for ovarian and breast cancer diagnosis
